<SEC-DOCUMENT>0001571049-17-007326.txt : 20170809
<SEC-HEADER>0001571049-17-007326.hdr.sgml : 20170809
<ACCEPTANCE-DATETIME>20170809163021
ACCESSION NUMBER:		0001571049-17-007326
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20170809
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170809
DATE AS OF CHANGE:		20170809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		171018325

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>t1702343_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event
reported): August 9, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CYCLACEL PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>0-50626</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B>91-1707622</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(State or other jurisdiction</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of incorporation)</B></P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Commission File Number)</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(IRS Employer</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Identification No.)</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>200 Connell Drive, Suite 1500</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Berkeley Heights, NJ 07922</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive offices
and zip code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code: (908) 517-7330</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Former Name or Former Address, if Changed
Since Last Report)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see </I>General
Instruction A.2. below): </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.95pt; text-indent: -17.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.95pt; text-indent: -17.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 24.5pt">Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Emerging growth company&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 24.5pt">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 2.02 Results of Operations and Financial Condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information set forth under this &ldquo;Item
2.02. Results of Operations and Financial Condition,&rdquo; including the exhibit attached hereto, shall not be deemed &ldquo;filed&rdquo;
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference
into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such
filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Attached as Exhibit 99.1 is a copy of a
press release of Cyclacel Pharmaceuticals, Inc. (the &ldquo;<B>Company</B>&rdquo;), dated August 9, 2017, announcing certain financial
results for the second quarter ended June 30, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company will conduct a conference call
to review its financial results on August 9, 2017, at 4:30 p.m., Eastern Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 10%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibit</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 89%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Press release announcing financial results for the second quarter ended June 30, 2017, dated August 9, 2017.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Paul McBarron</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Paul McBarron</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Executive Vice President&mdash;Finance,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer and Chief Operating Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: August 9, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>t1702343_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 63%; font-size: 10pt">&nbsp;<IMG SRC="t1702343_ex99-1logo01.jpg" ALT=""></td>
    <td style="width: 37%; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel
    Pharmaceuticals, Inc.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="t1702343_ex99-1logo02.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CYCLACEL PHARMACEUTICALS REPORTS SECOND
QUARTER 2017 FINANCIAL RESULTS&#9;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><I>&ndash;
Conference Call Scheduled August 9, 2017 at 4:30 p.m. EDT &ndash;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Berkeley Heights, NJ, August 9,
2017</B> - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; &quot;Cyclacel&quot; or the &quot;Company&quot;), a clinical-stage
biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative,
targeted medicines for cancer and other proliferative diseases, today reported its financial results and business highlights for
the second quarter ended June 30, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Company's net loss applicable
to common shareholders for the three months ended June 30, 2017 was $2.2 million or $0.50 per share, compared to net loss applicable
to common shareholders of $3.0 million, or $1.01 per share for the second quarter of 2016. As of June 30, 2017, cash and cash
equivalents totaled $13.6 million. <I>Pro forma</I> cash and cash equivalents as of June 30, 2017 totaled $27.4 million after
including $13.8 million in proceeds, net of expenses, received in the Company&rsquo;s underwritten offering completed on July
21, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&ldquo;As a result of the completion
of our recent offering, in which existing and new investors participated, we are able to advance the clinical investigation of
CYC065, our Cyclin Dependent Kinase (CDK) 2/9 inhibitor, in selected, molecularly-defined patient populations,&rdquo; said Spiro
Rombotis, President and Chief Executive Officer of Cyclacel. &ldquo;We have selected a recommended Phase 2 dose for CYC065 from
part 1 of a dose-escalating, Phase 1, first-in-human, study of CYC065. Data from this study evidenced durable target engagement
and Mcl-1 biomarker suppression at well tolerated doses with initial evidence of anticancer activity in patients with Mcl-1 and/or
cyclin E overexpression or amplification. Our top priority is to finalize designs for a Phase 1/2 study testing CYC065 in combination
with venetoclax, a Bcl-2 inhibitor approved for chronic lymphocytic leukemia, an indication in which we believe Mcl-1 suppression
may be beneficial. In parallel, we will enroll a new part 2 of the Phase 1 study in patients with advanced solid tumors testing
additional dosing schedules. We look forward to reporting our progress, commencement of these studies and data, as they arise.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Business Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Transcriptional Regulation Program:
CYC065 CDK inhibitor</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Selected
                                         a recommended Phase 2 dose (RP2D) from part 1 of a dose-escalating, Phase 1, first-in-human,
                                         clinical study. RP2D was determined at dosing level 6, which enrolled 10 patients with
                                         advanced cancers. Prolonged reduction of the Mcl-1 biomarker was observed in 7 out of
                                         9 evaluable patients for at least 24 hours following a single dose of CYC065, which was
                                         generally well tolerated. Preliminary anticancer activity was observed in three patients
                                         with Mcl-1, MYC and Mcl-1/cyclin E amplified cancers. The trial is being conducted at
                                         the Dana Farber Cancer Institute in Boston.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Part
                                         2 of the study will enroll patients with advanced solid tumors,
                                         in particular cyclin E amplified tumors. Such tumors include subsets of high grade serous
                                         ovarian and uterine cancers. Part 2 will evaluate CYC065 in a more intensive schedule
                                         for 2 days per week, for 2 weeks of a three-week cycle. Biospecimens will be collected
                                         for assessment of biomarkers related to CYC065&rsquo;s mechanism of action.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Wingdings">&thorn;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> 200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922, USA
Tel +1 908 517 7330 Fax +1 866 271 3466</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> 1 James Lindsay Place, Dundee, DD1 5JJ, UK Tel +44 1382 206 062
Fax +44 1382 206 067</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>www.cyclacel.com </U>&ndash; <U>info@cyclacel.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>SEAMLESS Study</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
                                         abstract of the results of the Phase 3 study of oral sapacitabine in elderly patients
                                         with acute myeloid leukemia (AML) has been submitted to the American Society of Hematology
                                         (ASH), and if accepted, will be the subject of an oral or poster presentation at the
                                         59<SUP>th</SUP> ASH Annual Meeting to be held December 9 - 12, 2017. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>July Underwritten Offering</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                         July 21, 2017, the Company announced the closing of an underwritten offering, with net
                                         proceeds of approximately $13.8 million after deducting underwriting discounts and commissions
                                         and other estimated offering expenses, including full exercise of the underwriters&rsquo;
                                         overallotment option. The Company issued and sold in the offering (i) 3,154,000 Class
                                         A Units, each consisting of one share of the Company&rsquo;s common stock, and a warrant
                                         to purchase one share of common stock, and (ii) 8,872 Class B Units, each consisting
                                         of one share of the Company&rsquo;s Series A Convertible Preferred Stock convertible
                                         into 500 shares of common stock at the initial conversion price, and a warrant to purchase
                                         a number of shares of common stock equal to $1,000 divided by the conversion price. The
                                         price to the public in the offering was $2.00 per Class A Unit and $1,000 per Class B
                                         Unit.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Subsequent
                                         to the closing of the offering, holders of 7,613 (86%) shares out of 8,872 shares outstanding
                                         of Series A Preferred Stock elected to convert their shares into 3,806,500 shares of
                                         common stock. Following such conversions, 11,400,447 shares of common stock and 1,259
                                         (14%) shares of Series A Preferred Stock remain outstanding as of August 8, 2017.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Financial Highlights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">As of June 30, 2017, cash and cash
equivalents totaled $13.6 million, compared to $16.5 million on December 31, 2016. After the July offering, <I>pro forma </I>cash
and cash equivalents are $27.4 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Revenue for the three months ended
June 30, 2017 were $0 compared to $0.2 million for the same period of the previous year. Revenue is primarily related to previously
awarded grants from the UK government being recognized over the period to progress IND-directed preclinical development of CYC140,
a novel, orally available, Polo-Like Kinase 1 (PLK 1) inhibitor, completed in November 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Research and development expenses
were $1.2 million compared to $2.6 million for the same period in 2016. The decrease was primarily due to reduced study and clinical
supply costs associated with completion of the SEAMLESS study and completion of preclinical development of CYC140.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses for
the three months ended June 30, 2016 and 2017 remained flat at $1.3 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Other income (expense), net for the
three months ended June 30, 2017 was $34,000, compared to $0.2 million for the same period of the previous year. The decrease
in other income (expense) is primarily related to foreign exchange movements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The UK government research &amp; development
tax credit for the quarter was $0.3 million, compared to $0.6 million for the same period of the previous year. During the quarter,
we also recognized cash received for the 2016 tax credit of $1.8 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Net loss for the three months June
30, 2017 was $2.2 million compared to $3.0 million for the same period in 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Conference call information:&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">US/Canada call: (877) 493-9121 / international
call: (973) 582-2750&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">US/Canada archive: (800) 585-8367
/ international archive: (404) 537-3406&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Code for live and archived conference
call is 64524973</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">For the live and archived webcast,
please visit the Corporate Presentations page on the Cyclacel website at www.cyclacel.com. The webcast will be archived for 90
days and the audio replay for 7 days.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About Cyclacel Pharmaceuticals,
Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Cyclacel Pharmaceuticals is a clinical-stage
biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative,
targeted medicines for cancer and other proliferative diseases. Cyclacel's transcriptional regulation program is evaluating CYC065,
a CDK inhibitor, in patients with advanced cancers. The DNA damage response program is evaluating a sequential regimen of sapacitabine
and seliciclib, a CDK inhibitor, in patients with BRCA positive, advanced solid cancers. Cyclacel's strategy is to build a diversified
biopharmaceutical business focused in hematology and oncology based on a pipeline of novel drug candidates. For additional information,
please visit <U>www.cyclacel.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Forward-looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This news release contains certain
forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from
historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements
include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates,
the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and
plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product
candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale
or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates,
the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on
collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to
consider statements that include the words &quot;may,&quot; &quot;will,&quot; &quot;would,&quot; &quot;could,&quot; &quot;should,&quot;
&quot;believes,&quot; &quot;estimates,&quot; &quot;projects,&quot; &quot;potential,&quot; &quot;expects,&quot; &quot;plans,&quot;
&quot;anticipates,&quot; &quot;intends,&quot; &quot;continues,&quot; &quot;forecast,&quot; &quot;designed,&quot; &quot;goal,&quot;
or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description
of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic
and other filings we file with the Securities and Exchange Commission and are available at <U>www.sec.gov</U>. Such forward-looking
statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements,
whether as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 20%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contacts</B></FONT></td>
    <TD STYLE="width: 80%; text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company:</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul McBarron, (908) 517-7330, <U>pmcbarron@cyclacel.com</U></FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor Relations:</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Russo Partners LLC, Alexander Fudukidis, (646)
942-5632, <U>alex.fudukidis@russopartnersllc.com</U></FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-weight: normal">&copy;
Copyright 2017 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel&reg; are trademarks of Cyclacel
Pharmaceuticals, Inc. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CYCLACEL PHARMACEUTICALS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(In $000s, except share and per share
amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three&nbsp;Months&nbsp;Ended<BR> June 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six months&nbsp;Ended<BR> June 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: -0.1in; padding-left: 0.1in">Revenues:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Grant revenue</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">222</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">361</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,637</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,222</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,136</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,534</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,345</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,267</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,729</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,648</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,982</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,489</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,865</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,182</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Operating loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,760</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,489</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,504</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,182</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Foreign exchange gains (losses)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">138</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">318</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(43</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Other income, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">38</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">879</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Total other income (expense)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">169</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">34</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">379</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">866</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Loss before taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,591</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,455</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,125</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,316</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Income tax benefit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">626</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">268</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,119</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">574</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,965</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,187</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,006</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,742</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Dividend on convertible exchangeable preferred shares</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(50</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(50</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(100</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(100</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Net loss applicable to common shareholders</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,015</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,237</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(6,106</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,842</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Basic and diluted earnings per common share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Net loss per share&thinsp;&ndash;&thinsp;basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1.01</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.50</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2.05</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.88</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Weighted average common shares outstanding</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,000,192</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,434,441</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,982,508</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,353,333</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral
part of these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CYCLACEL PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(In $000s, except share, per share,
and liquidation preference amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">June 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">(Unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: -0.1in; padding-left: 0.1in">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Current assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">16,520</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">13,591</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,097</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,460</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.35in">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,617</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,051</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Property, plant and equipment (net)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">45</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">32</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.35in">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">19,662</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">16,083</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,497</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,038</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Accrued and other current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,762</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,281</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.35in">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,259</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,319</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Other liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">130</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">128</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.35in">Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,389</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,447</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Commitments and contingencies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Stockholders&rsquo; equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 16.2pt">Preferred stock, $0.001 par value; 5,000,000 shares authorized at December&nbsp;31, 2016 and June 30, 2017; 335,273 shares issued and outstanding at December&nbsp;31, 2016 and June 30, 2017. Aggregate preference in liquidation of $4,006,512 at December&nbsp;31, 2016 and June 30, 2017.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 16.2pt">Common stock, $0.001 par value; 100,000,000 shares authorized at December&nbsp;31, 2016 and June 30, 2017; 4,256,829 and 4,439,947 shares issued and outstanding at December&nbsp;31, 2016 and June 30, 2017 respectively.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">350,051</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">351,148</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Accumulated other comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(743</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(736</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(335,039</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(338,780</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.35in">Total stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14,273</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,636</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.35in">Total liabilities and stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">19,662</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">16,083</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SOURCE: Cyclacel Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>t1702343_ex99-1logo01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 t1702343_ex99-1logo01.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 1 "U P$1  (1 0,1 ?_$ *D  0 " P$! 0$
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M%KQ[GX\\=8P;.;_JWE6U:F6^(.5V=T6URMDPS+-5'* KQ%]Q[<IES"/X-X(
MGVI+->TQ@'H<>@<[,/OGNFZK\N[EX.)O^RL+$O''!F1FQ D@RHD5T<>-V#7\
M.E<,_P"FC8]BD&[=GMQS^+<@1KA8YI<G F%P6BR<*=W1XV M92MCU(:P%8!
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MHXC.DZ*F:I L(*/"E<#(@0A414K!_&%3Y(VA.RE"31*C:E,F[#U%\V[QZHV
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MI^W'C J6J>&UJY8)![ER'W QEFA\TL3%)L> @2TBJQK6672FU3J$,Y W8W[
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**4XI3BE.*5__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>t1702343_ex99-1logo02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 t1702343_ex99-1logo02.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ %P). P$1  (1 0,1 ?_$ &\  0 " @,  P
M       '" 8) P0% 0(* 0$                     $   !0,#! (" @("
M P     ! @,$!0 &!Q'4%R$25Y<3"#$402)A%7$6,B,D$0$
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M!W ;40UUH+<XBE+/F,;6?(6#*NIJT%X9O_HY%^Y7=OUV91,4H/5W(BX.Z2,
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>KC:Y$SK@+ELU^)L4S0!77 7/>)"]?C(<WX*-!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
